BUPE2021.COMBUPE2021.COM
  • Home
  • Presentations
  • Posters
  • Info
    • ——————————
      • Call For Presentations, Posters, etc
      • CME Information
        • Conference Chairs
      • Presentations – Preview
    • ——————————
      • Press & Media
        • Contact Us
        • Speakers
    • ——————————
      • Conference Information
      • Terms and conditions
      • Tickets
    • ——————————
      • Educational Support
      • Satellite Symposia
      • Sponsorship & Exhibits
  • Register Now to Watch
  • Login
  • Get Started Now!
  • Home
  • Presentations
  • Posters
  • Info
    • ——————————
      • Call For Presentations, Posters, etc
      • CME Information
        • Conference Chairs
      • Presentations – Preview
    • ——————————
      • Press & Media
        • Contact Us
        • Speakers
    • ——————————
      • Conference Information
      • Terms and conditions
      • Tickets
    • ——————————
      • Educational Support
      • Satellite Symposia
      • Sponsorship & Exhibits
  • Register Now to Watch
  • Login
  • Get Started Now!

Posters

AStevens Hospice Education Poster 12.15_150DPI
12/152021

Evaluation of Strategies to Enhance Hospice Patient and Family’s Knowledge and Confidence of Commonly Used Medications

Posters
https://bupe2021.com/wp-content/uploads/2020/06/AStevens-poster-video_final.mp4

 

Poster – Evaluation of Strategies to Enhance Hospice Patient and Family’s Knowledge
and Confidence of Commonly Used Medications

Abby Stevens, PharmD1,2, Ryan Costantino PharmD, MS, BCPS, BCGP1, Mary Lynn McPherson, PharmD, MA, MDE, BCPS1
1 University of Maryland School of Pharmacy, 2 MedStar Health

Background:

Approximately 50% of the patient deaths of those enrolled in hospice care in 2018, died at home.1
• Twenty-three percent of informal caregivers (IFC) caring for patients in home hospice agreed it is difficult to decide which
analgesic to give, and 21% agreed it is difficult to decide what dose of analgesic medication to administer.2
• The Consumer Assessment of Healthcare Providers and Systems (CAHPS) hospice survey is distributed by the Centers
for Medicare and Medicaid (CMS) to informal caregivers after the death of a hospice patient to evaluate eight domains of
care: communication with family, getting timely help, treating patient with respect, emotional and spiritual support, help for
pain and symptoms, training family to care for patient, rating of the hospice, willingness to recommend the hospice.3
• Infographics provide complex information to various audiences in an easy to comprehend format with the use of pictures and
images.4

Keywords: hospice, caregiver, patient, family, palliative medicine, palliative care

Presentation Slide Handout: Poster Presentation PDF

DOI: 10.5055/bupe.21.pp.0095

References:

1. NHPCO Facts and Figures 2020 Edition. National Hospice and Palliative
Care Organization. 2020 Aug 20.
2. J Pain Symptom Manage. 2004;27(2):114-124.
3. CAHPS® Hospice Survey | CMS. Accessed April 11, 2021.
4. Chin Med J (Engl). 2018;131(20):2514-2517.

Read more
LINDA YOUNG BUPE2021 Poster Presentation Slide 1
12/082021

Limited Observational Case Study Documenting The Transition of Patients Off Medication-Assisted Treatment With The Use of XR-Buprenorphine

Posters
https://bupe2021.com/wp-content/uploads/2020/06/Young-Final-Poster-Presentation.mp4

Poster – Limited Observational Case Study Documenting The Transition of Patients
Off Medication-Assisted Treatment With The Use of XR-Buprenorphine

Linda Young, DNP
Owner/Provider, Compassionate Care, Inc., North Smithfield, RI 02896

Abstract:

This was a limited observational case study, documenting the reported withdrawal symptoms of three Medication-assisted treatment (MAT) patients, after the cessation of subcutaneously injected XR (extended release) buprenorphine. The participants were two females ages 39 (participant A) and 37 (participant B) and one male 40 (participant C) years old. Each participant had a diagnosis of opioid use disorder (OUD), had at least three years of documented opioid cessation, were stable in all aspects of their lives and were requesting to be transitioned off MAT. The participants were given injections of XR-buprenorphine for six consecutive months and then the treatment was discontinued. Each participant met with the clinician monthly and a COWS (clinical opioid withdrawal scale) and a urine for toxicology was obtained. The female participants were followed for twelve and eleven months respectively and the male for nine months. The results of the COWS scores were zero (0) for all consecutive months of the study and the urine tox screens were negative for opioid use for all consecutive months, for all three participants. Although the results of this case study are limited, they do indicate that the use of XR-buprenorphine to transition patients off MAT may be a novel and innovative way to assist stable patients with reclaiming their previously opioid free lives.

Keywords: Medication-assisted treatment, XR-buprenorphine, opioid use disorder, buprenorphine

Presentation Slide Handout: Poster Presentation Handouts

DOI: 10.5055/bupe.21.pp.0090

 

Read more
BUPE2021 Poster -Dr Krishna S Dokku Slide
11/102021

Poster – A randomised controlled study to compare analgesic efficacy of sublingual buprenorphine versus intravenous tramadol in patients undergoing mastectomy

Posters
https://bupe2021.com/wp-content/uploads/2020/06/BUPE2021-Dr-Krishna-S-Dokku.mp4

Poster – A randomised controlled study to compare analgesic efficacy of sublingual buprenorphine
versus intravenous tramadol in patients undergoing mastectomy

Krishna Sumanth Dokku, Srinivasa Shyam Prasad Mantha, Abhijit Nair, Basanth Kumar Rayani
Department of Anaesthesiology, Basavatarakam Indo- American Cancer Hospital and Research Institute, Hyderabad, India

Abstract:

Sublingual (SL) buprenorphine has been used by researchers to manage acute postoperative pain. In this study, we compared analgesic efficacy of SL buprenorphine to intravenous tramadol in managing postoperative pain after mastectomy.

Postmastectomy pain syndrome (PMPS) is a chronic neuropathic pain observed in women who undergo breast surgery. Poorly managed postoperative pain after breast surgery is one of the important causes of PMPS. Buprenorphine is available for clinical use in the form of sublingual (SL) tablets which have been used for managing acute postoperative pain with reasonable success.

Presentation Slide Handout: Poster Presentation

DOI: 10.5055/bupe.21.pp.0085

 

Read more
BUPE Subgroup Analysis Poster 10-22-21
11/082021

Poster – The Effects of CARA on Buprenorphine prescribing patterns amongst providers

Posters
https://bupe2021.com/wp-content/uploads/2020/06/Liu-Poster-Presentation.mp4

Poster – The Effects of CARA on Buprenorphine prescribing patterns amongst providers

Jonathan Liu MD, Henry Young MD

Abstract:

Background: Buprenorphine is a mainstay of FDA approved Medication Assisted Treatment (MAT) used to treat OUD. Access remains a barrier to widespread treatment.

Purpose: In 2016, CARA sought to increase MAT access by allowing waivered Nurse Practitioners (NPs) and Physician Assistants (PAs) to prescribe buprenorphine for MAT. NP and PA written prescriptions have increased annually alongside the number of licensed providers. Unclear is whether increasing prescriptions can be attributed to each provider prescribing more, an increase in providers, or both. We examined the effects of CARA on prescribing patterns among advanced practice providers.

Procedures: The number of buprenorphine prescriptions written in the US by NPs, PAs, and physicians from 2012-2017 was collected using the IQVIA database, which represents 92% of all US retail prescriptions. The number of providers was obtained from the providers’ respective licensing agencies. Descriptive statistics were used to analyze the data. Prescriptions per provider for PAs, NPs and physicians and physicians increased 8%, 28% and 4%, the year CARA took effect, compared to 14%, 19% and 9% the year before.

Conclusions: Total buprenorphine prescriptions and buprenorphine prescriptions per provider increased annually for all provider types. However, the prescriptions per provider increased for NPs, but decreased for PAs the year CARA was implemented.

Presentation Slide Handout: Poster Presentation PDF

DOI: 10.5055/bupe.21.pp.0080

 

Read more
BUPE Subgroup Analysis Poster 10-22-21
11/022021

Poster – Buprenorphine Buccal Film for Chronic Low Back Pain in 2 Double-blind, Placebo-controlled, Randomized Withdrawal Trials: A Pooled Analysis of Subgroups Based on Baseline Pain Severity

Posters
https://bupe2021.com/wp-content/uploads/2020/06/Ko_Subgroup-Analysis-Poster.mp4

Poster –

Buprenorphine Buccal Film for Chronic Low Back Pain in 2 Double-blind, Placebo-controlled, Randomized Withdrawal Trials:
A Pooled Analysis of Subgroups Based on Baseline Pain Severity

Mancia Ko, PharmD1; Gary Cutter, PhD2,3; Todd Kunkel, PharmD1

1 BioDelivery Sciences International, Inc., Raleigh, NC, USA; 2 Pythagoras, Inc., Birmingham, AL, USA; 3 University of Alabama at Birmingham School of Public Health, Department of Biostatistics, Birmingham, AL, USA

Buprenorphine Buccal Film (BELBUCA®)

  • —Buprenorphine is an atypical opioid and a partial µ-opioid receptor agonist, with demonstrated efficacy as an analgesic and favorable safety properties that may provide an improved risk-benefit profile relative to other opioids1
  • —As with all Schedule II long-acting opioids, buprenorphine buccal film (BBF) is approved by the US Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate2
  • —Two previous phase 3 clinical trials established the efficacy of BBF for treating chronic low back pain in opioid-naive3 and opioid-experienced4 subjects (ClinicalTrials.gov NCT01633944 and NCT01675167, respectively)
  • —Both studies used an enriched enrollment, randomized withdrawal design that consisted of an open-label BBF titration phase followed by a randomized, double-blind phase in which subjects either continued treatment with BBF or were switched to placebo3,4 (Figure 1)
  • —After 12 weeks of double-blind treatment, mean average daily pain scores worsened significantly less from baseline in subjects who continued use of BBF than in those who switched to placebo3,4
  • —Subjects in the BBF group also had significantly lower pain scores at Week 1 and at all subsequent time points through Week 123,4

Objective

—This post hoc analysis pooled data from both aforementioned clinical trials to characterize further the efficacy of BBF on the basis of baseline pain severity

Presentation Slide Handouts: Poster Presentation

DOI: 10-5055-bupe-21-pp-0070

References:

1.Marshall B, et al. Pain Manag. 2019;9(2):131-138.
2.Webster LR, et al. Adv Ther. 2020;37(11):4685-4696.
3.United States Drug Enforcement Administration. Drug scheduling. https://www.dea.gov/drug-scheduling.
4.Belbuca. Package insert. BioDelivery Sciences International, Inc.; 2019.
5.Webster LR, et al. Pain Med. 2016;17(6):1112-1130.
6.Kopecky EA, et al. J Clin Pharmacol. 2017;57(4):500-512.
7.Shram MJ, et al. J Clin Psychopharmacol. 2015;35(3):242-9.

Read more
BUPE Second Combo Poster 10-22-21
11/022021

Poster – Pharmacokinetic and Pupillometry Outcomes from a Phase 1 Placebo-controlled Trial to Compare the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride

Posters
https://bupe2021.com/wp-content/uploads/2020/06/Webster_Secondary-Combo-Poster.mp4

Poster – Pharmacokinetic and Pupillometry Outcomes from a Phase 1 Placebo-controlled Trial
to Compare the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride

Lynn Webster, MD1; Jacqueline Cater, PhD2; Thomas Smith, MD3

1 Center for U.S. Policy, Salt Lake City, UT, USA; 2 ICON plc, Philadelphia, PA, USA; 3 BioDelivery Sciences International, Inc., Raleigh, NC, USA

Background

  • —The opioid crisis has led to increased concern about the safety of opioids administered for chronic pain, especially regarding abuse and respiratory depression–associated death1
  • —As a partial μ-opioid receptor agonist, buprenorphine has unique properties that distinguish it from full μ-opioid receptor agonists
    • Buprenorphine is classified as a Schedule III drug because it has a lower abuse potential than full µ-opioid receptor agonists2,3
  • —Buprenorphine buccal film (BELBUCA®, BBF) is approved by the US Food and Drug Administration for use in patients with pain severe enough to require daily, around-the-clock, long-term opioid treatment and for whom alternative treatment options are inadequate4
  • —In this phase 1 study, evaluation of the primary endpoint revealed immediate-release oxycodone administration led to a significant, dose-dependent decrease in respiratory drive, whereas BBF did not (ClinicalTrials.gov Identifier: NCT03996694)
  • —The pharmacokinetic and pupillometry outcomes presented here were chosen because of their relevance for respiratory safety and potential risk for abuse
    • The abuse quotient (AQ) is a quantitative measure of pharmacokinetic parameters to compare an aspect of abuse potential across opioids5
    • oPrevious studies have shown a relationship between pupil constriction and “drug liking” in the context of opioid abuse6,7

Purpose

—Here we report secondary outcomes from the aforementioned phase 1 clinical trial, including effects of BBF and immediate-release oral oxycodone on pharmacokinetic, and pupillometry assessments.

 

Presentation Slide Handouts: Poster Presentation

DOI: 10-5055-bupe-21-pp-0065

References:

1.Marshall B, et al. Pain Manag. 2019;9(2):131-138.
2.Webster LR, et al. Adv Ther. 2020;37(11):4685-4696.
3.United States Drug Enforcement Administration. Drug scheduling. https://www.dea.gov/drug-scheduling.
4.Belbuca. Package insert. BioDelivery Sciences International, Inc.; 2019.
5.Webster LR, et al. Pain Med. 2016;17(6):1112-1130.
6.Kopecky EA, et al. J Clin Pharmacol. 2017;57(4):500-512.
7.Shram MJ, et al. J Clin Psychopharmacol. 2015;35(3):242-9.

Read more
BUPE Primary Poster 10-22-21
11/022021

Poster – Respiratory Outcomes from a Phase 1, Placebo-controlled Trial to Compare the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride

Posters
https://bupe2021.com/wp-content/uploads/2020/06/Webster_Primary-Outcomes-Poster.mp4

Poster – Respiratory Outcomes from a Phase 1, Placebo-controlled Trial to Compare the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride

Lynn Webster, MD1; Jacqueline Cater, PhD2; Thomas Smith, MD3

1 Center for U.S. Policy, Salt Lake City, UT, USA; 2 ICON plc, Philadelphia, PA, USA; 3 BioDelivery Sciences International, Inc., Raleigh, NC, USA

Background

  • —Respiratory depression is the leading cause of death due to opioid overdose1
  • —Inhibition of respiratory drive (ie, the ability of neuronal respiratory centers to control and regulate ventilation) is a major contributor to respiratory depression2
  • —Buprenorphine is a partial µ-opioid receptor agonist that exhibits a ceiling effect for respiratory depression when administered intravenously, unlike full µ-opioid receptor agonists (eg, morphine, oxycodone, fentanyl)3,4
  • —Partial agonism only refers to receptor-level activation and not analgesic efficacy, as buprenorphine provides analgesic efficacy comparable to that of full µ-opioid receptor agonists5
  • −This partial agonism at the µ-opioid receptor, together with antagonism at the κ and δ opioid receptors and agonism at the nociceptin receptor (formerly known as opioid receptor-like 1 or ORL-1), may play a role in limiting common opioid-related adverse events (AEs) such as respiratory depression

Purpose

—This study compared the effects of buprenorphine buccal film (BBF; BELBUCA®) with the effects of immediate-release oral oxycodone on respiratory outcomes to differentiate impact of a partial µ-opioid receptor agonist (ie, BBF) from that of a full µ-opioid receptor agonist (ie, oxycodone)

Presentation Slide Handouts: Poster Presentation

DOI: 10-5055-bupe-21-pp-0060

References:

1. White JM, Irvine RJ. Addiction. 1999;94(7):961-972.
2.Pattinson KTS. Br J Anaesth. 2008;100(6):747-758. doi:10.1093/bja/aen094
3.Dahan A, et al. Br J Anaesth. 2005;94(6):825-834. doi:10.1093/bja/aei145
4.Dahan A, et al. Br J Anaesth. 2006;96(5):627-632. doi:10.1093/bja/ael051
5.Gudin J, Fudin J. Pain Ther. 2020;9(1):41-54. doi:10.1007/s40122-019-00143-6
6.Hale M, et al. J Pain Res. 2017;10: 233-240. doi:10.2147/JPR.S120170
7.Rauck RL, et al. Postgrad Med. 2016;128(1):1-11. doi:10.1080/00325481.2016.1128307
8.Gimbel J, et al. Pain. 2016;157(11):2517-2526. doi:10.1097/j.pain.0000000000000670

Read more
icoo.20.pp.0051_ICOO Poster_Cioe_96DPI
10/292020

A Systematic Review of Patient and Provider Perspectives of Medications for Treatment of Opioid Use Disorder

Posters

A Systematic Review of Patient and Provider Perspectives of Medications for Treatment of Opioid Use Disorder

This systematic review focuses on published manuscripts that have assessed the preferences and attitudes of MOUD by providers and/or patients.

The aim of this systematic review is to disentangle the opinions about these medications to understand how patient and provider beliefs may impact choice of MOUD and the efficacy of addiction treatment.

Presented by: Katharine Cioe, BS1,Breanne E. Biondi, MPH2, Rebecca Easly, BA1, Amanda Simard, BS1,  Xiao Zheng3, Sandra A. Springer, MD2,4

1Frank H. Netter School of Medicine, 2Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, 3Yale University, 4Center for Interdisciplinary Research on AIDS, Yale University School of Public Health

Poster in PDF format: icoo.20.pp.0051_ICOO Poster_Cioe

Read more
ICOO Resp Drive Poster_Final_150DPI
08/172020

A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone on Respiratory Drive

Posters 1

A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride on Respiratory Drive

Presented by:

Lynn Webster, MD1; Jacqueline Cater, PhD1; Thomas Smith, MD

Video Poster:

https://bupe2021.com/wp-content/uploads/2020/08/icoo.20.pp_.0006_ICOO_Resp_Drive_Slides_FINAL-14Aug2020.mp4

Poster in PDF format:

icoo.20.pp.0008_ICOO Resp Drive Poster_Final

Read more
Search
Latest Presentations
  • Buprenorphine in Medicine Introductory Webinar January 20, 2022
  • Buprenorphine: Not Just Another Opioid – Mythbusting the Worlds Most Interesting Opioid January 19, 2022
  • Buprenorphine Update – Intracellular Nuances of Buprenorphine January 18, 2022
  • Buprenorphine: The Opioid that Cried ‘Partial Agonist” January 17, 2022
Categories
  • Posters
  • Presentations
  • Presentations for CME Review

Journal of Opioid Management (JOM) has assembled the best and brightest minds in opioid analgesics who will explore the benefits and challenges of using buprenorphine to treat patients across the spectrum.

BUPE2021 is presented by the Journal of Opioid Management. We are dedicated to presenting the latest research and practice for managing patients on opioid therapies.

INFORMATION
  • Terms and conditions
  • Privacy Statement
Looking for more? Sign up today!

    Contact Us
    jom@pnpco.com
    Copyright 2022 Weston Medical Publishing, LLC - All Rights Reserved
    This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    Privacy Statement


    Privacy and User Data Policy

    GDPR Update:

    The data collected from registered and non-registered users of this journal falls within the scope of the standard functioning of peer-reviewed journals. It includes information that makes communication possible for the editorial process; it is used to informs readers about the authorship and editing of content; it enables collecting aggregated data on readership behaviors, as well as tracking geopolitical and social elements of scholarly communication.

    This journal’s editorial team uses this data to guide its work in publishing and improving this journal. Data that will assist in developing this publishing platform may be shared with its developer Public Knowledge Project in an anonymized and aggregated form, with appropriate exceptions such as article metrics. The data will not be sold by this journal or PKP nor will it be used for purposes other than those stated here. The authors published in this journal are responsible for the human subject data that figures in the research reported here.

    Those involved in editing this journal seek to be compliant with industry standards for data privacy, including the European Union’s General Data Protection Regulation (GDPR) provision for “data subject rights” that include (a) breach notification; (b) right of access; (c) the right to be forgotten; (d) data portability; and (e) privacy by design. The GDPR also allows for the recognition of “the public interest in the availability of the data,” which has a particular saliency for those involved in maintaining, with the greatest integrity possible, the public record of scholarly publishing.

    Requests per item (a) through (e) above should be sent to the journal's mailbox, jom(at)pnpco.com

    The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

    What Data does this Website Process?

    The system, based the PKP Open Journal System applications, process personal data as a fundamental part of their operations. Most data is only provided by consent, ie. through manual user registration, though some visitation data (eg. cookies, usage logs) may also be recorded.

    User Registration Data

    When a visitor creates a user account in a PKP application, the following personal information is processed and stored (with some minor variation between OMP and OJS, and from version to version):

    ●   Salutation

    ●   First name*

    ●   Middle name

    ●   Last name*

    ●   Suffix

    ●   Username

    ●   Gender

    ●   Password (encrypted)

    ●   Email address*

    ●   ORCiD ID

    ●   Website

    ●   Mailing Address

    ●   Country

    ●   Phone

    ●   Fax

    ●   Affiliation

    ●   Biography

    ●   Registration date

    ●   Last login date

    ●   Locales

    ●   Reviewing interests

    ●   Role registrations (author, reader, and/or reviewer)

    Only the username, first name, last name, email and password fields are required.

    Storage

    This information is stored in the application database. Only the user password

    is encrypted.

    Availability and Access

    This information is available to the user via their User Profile (and, with the exception of the username and dates, can be edited). System administrators, journal managers, and editors can also access and edit this data (except the username and dates) via the application back end. The data can be downloaded by journal managers in XML format. The data is not otherwise publicly available.

    Erasure

    This data can be erased by the journal manager using the Merge Users tool, without affecting any editorial records. The erasure is subject to the considerations raised in the section “Scholarly Publishing, Data Privacy, and the Public Interest”, above.

    Contributor Metadata Information

    When a manuscript is submitted to a PKP application, contributor information is included. Contributors can be authors, translators, volume editors, and so on. This information is stored as submission metadata and is provided as part of any published manuscript record. The following contributor information is collected:

    ●   Salutation

    ●   First name*

    ●   Middle name

    ●   Last name*

    ●   Email address*

    ●   Suffix

    ●   ORCiD ID

    ●   Website

    ●   Country*

    ●   Affiliation

    ●   Biography

    Only the first name, last name, email address and country fields are required.

    Storage

    This information is stored in the application database.

    Data Transfer

    We do not sell or transfer to third parties user information from this system.

    General Visitor Information

    PKP applications also collect general visitor usage data, including:

    ● Cookie information, to manage session history. Cookies are required to maintain a login session in PKP applications.

    ● Optionally, detailed usage log data, including: IP address; pages visited; date visited; and browser information, in application log files, as part of the Usage Statistics plugin. An anonymization option is available to privatize this information.

    ● Optionally, country, region and city information, in the metrics database. This data collection requires additional setup and is not enabled by default.

    Other data may be tracked, either on the server or via third parties:

    ● Script loads from CDN servers;

    ● IP address information (including date, browser, etc.) in web server logs (separate from application log files as part of the Usage Statistics plugin).

    Detailed instructions in limiting the amount of data you collect, and providing consent for the data you collect, can be found below.

    Storage

    ● Cookies: A cookie (usually titled “OJSSID” or “OMPSID”) is created when first visiting a PKP application and is stored on the visitor’s computer. It is only used to store a session ID, and to facilitate logins. (If the visitor blocks cookies, OJS will still work properly, though they will not be able to log in.)

    ● Usage Statistics log files: As part of the usage statistics framework and plugin, OJS may store detailed application log files in the submission files directory (configured as the files_dir parameter in the OJS config.inc.php file), in a “usageStats” directory.

    ● Geographical data: Filtered usage data, including possibly geographic data, is also stored in the OJS database, in a “metrics” table.

    Availability and Access

    ● Cookies: These are available via the visitor’s browser settings.

    ● Usage Statistics log files: Only individuals with server file access can access application log files.

    ● Geographical data: Journal Managers can access filtered usage data by using the OJS usage report plugins.

    Erasure

    ● Cookies: These can be deleted via the visitor browser.

    ● Usage Statistics log files: These can be erased by system administrators with file access.

    ● Geographical data: This can only be erased by deleting records from the database directly, which also typically requires system administrator access.

    Portions of this privacy statement are copyright by Simon Fraiser University Licensed wth CC4.0-BY.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT